|
|
Article: Xenon Set To Enter Clinic With $31M Third-Round Financing.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
As its two lead products prepare for clinical trials, Canadian genetics company Xenon Pharmaceuticals Inc. secured a US$31 million financing.
The funds will support XEN401 for chronic and acute pain and XEN501 for acute termination and prevention of atrial and ventricular fibrillation. Currently in pre-investigational new drug application studies, the products could enter clinical trials later this year.
MX Associates LLP and LipoteRx Ltd. led the financing - a third institutional round for the Vancouver, British Columbia-based company. Several other investors, including New York-based Invesco Private Capital, participated.
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|